Summary
Abbott Laboratories reported solid financial results for the nine months ended September 30, 2013, with net sales reaching $16.19 billion, a 2.1% increase year-over-year. This growth was driven by performance in its Nutritional Products, Diagnostic Products, and Established Pharmaceutical Products segments, with notable contributions from Key Emerging Markets. The company's strategic separation of its proprietary pharmaceutical business into AbbVie Inc. on January 1, 2013, has significantly reshaped its financial statements, with AbbVie's results now presented as discontinued operations. This strategic move has reduced overall reported net earnings but has allowed Abbott to focus on its diversified healthcare portfolio. Operationally, Abbott demonstrated improved gross profit margins in the third quarter of 2013, reaching 50.7% compared to 49.0% in the prior year, signaling effective cost management and favorable segment performance. The company also made strategic acquisitions, notably IDEV Technologies and OptiMedica, to strengthen its Vascular and Diagnostic portfolios, respectively. Despite these positive developments, the company experienced a reduction in cash and cash equivalents due to the AbbVie separation, but maintains a strong liquidity position with significant unused lines of credit. Abbott also announced an increase in its quarterly dividend, signaling confidence in its future performance.
Financial Highlights
53 data points| Revenue | $4.80B |
| Cost of Revenue | $2.25B |
| Gross Profit | $2.42B |
| SG&A Expenses | $1.61B |
| Operating Expenses | $4.35B |
| Operating Income | $473.00M |
| Interest Expense | $37.00M |
| Net Income | $966.00M |
| EPS (Basic) | $0.62 |
| EPS (Diluted) | $0.61 |
| Shares Outstanding (Basic) | 1.55B |
| Shares Outstanding (Diluted) | 1.57B |
Key Highlights
- 1Net sales for the nine months ended September 30, 2013, increased by 2.1% to $16.19 billion, driven by growth in Nutritional, Diagnostic, and Established Pharmaceutical Products segments.
- 2Gross profit margin improved to 50.7% in Q3 2013, up from 49.0% in Q3 2012, indicating enhanced operational efficiency and product mix.
- 3The strategic separation of AbbVie Inc. was completed on January 1, 2013, with AbbVie's historical results reported as discontinued operations, significantly impacting overall net earnings comparison.
- 4Abbott completed two strategic acquisitions in August 2013: IDEV Technologies for $310 million and OptiMedica for $260 million plus potential milestones, bolstering its Vascular and Medical device offerings.
- 5Cash and cash equivalents decreased significantly due to the $5.9 billion transfer to AbbVie during the separation, but the company maintains robust liquidity with $5.0 billion in unused credit lines.
- 6The company announced a 57% increase in its quarterly dividend to $0.22 per share, effective February 2014, signaling confidence in its financial stability and future cash flows.
- 7Selling, general, and administrative expenses decreased by 9.7% in Q3 2013 and 6.1% year-to-date, largely due to the AbbVie separation and ongoing expense control initiatives.